Global Leading Market Research Publisher QYResearch announces the release of its latest report "Monkeypox Virus Vaccine - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032". Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Monkeypox Virus Vaccine market, including market size, share, demand, industry development status, and forecasts for the next few years. The global market for Monkeypox Virus Vaccine was estimated to be worth US2.2billionin2025andisprojectedtoreachUS 4.5 billion, growing at a CAGR of 10.8% from 2026 to 2032. The 2022-2023 global monkeypox outbreak (declared a Public Health Emergency of International Concern by WHO, July 2022-May 2023) exposed critical gaps in pandemic preparedness: limited vaccine stockpiles (fewer than 50 million doses globally), reliance on smallpox vaccines developed decades ago, and fragmented manufacturing capacity. For public health agencies and governments, the core pain points are threefold: (1) the need for rapid-response vaccine production against emerging orthopoxvirus threats, (2) ensuring equitable access across high-income and low-middle-income countries, and (3) maintaining stockpile readiness between outbreaks without wasteful expiration. The monkeypox virus vaccine market addresses these challenges by leveraging existing smallpox vaccine platforms (MVA-BN, LC16, OrthopoxVac) with demonstrated cross-protection efficacy, while advancing next-generation formulations with improved safety profiles and scalable manufacturing. 【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart) https://www.qyresearch.com/reports/5973291/monkeypox-virus-vaccine 1. Core Market Drivers and Public Health Context The monkeypox virus vaccine market is driven by three converging forces: Driver 1: Endemicity Expansion and Outbreak Risk Prior to 2022, monkeypox was primarily confined to Central and West Africa (endemic in 11 countries). The 2022-2023 global outbreak (118,000+ confirmed cases across 120+ countries) demonstrated the virus's pandemic potential. As of March 2026, sustained human-to-human transmission continues in DRC and Nigeria (estimated 6,000-8,000 annual cases), with sporadic cases elsewhere. Orthopoxvirus outbreaks are expected to recur every 3-5 years, requiring ongoing vaccine preparedness. Driver 2: Smallpox Stockpile Replacement The WHO's global smallpox vaccine stockpile (originally created for bioterrorism preparedness) was approximately 75 million doses in 2010 but has declined to 45 million doses (2025) due to expiration without replenishment. Many countries (US, UK, Canada, Japan, EU members) are now actively rebuilding orthopoxvirus vaccine stockpiles specifically for monkeypox, using newer generation vaccines with better safety profiles (MVA-BN is non-replicating, safe for immunocompromised individuals, unlike first-generation smallpox vaccines). Driver 3: Regulatory and Funding Support Following the 2022-2023 outbreak, several funding mechanisms have been established: WHO's Mpox (monkeypox) Strategic Preparedness and Response Plan (2024-2027): US$ 125 million for surveillance, diagnostics, and vaccines US BARDA (Biomedical Advanced Research and Development Authority) Project NextGen (2025): US$ 200 million for orthopoxvirus vaccine advanced development EU HERA (Health Emergency Preparedness and Response Authority) Mpox vaccine procurement (2025): US$ 150 million for 10 million doses Exclusive Expert Insight (March 2026 Update): The Q4 2025 emergence of a novel monkeypox clade (Clade Ib) in eastern DRC with higher transmissibility (R0 estimated 1.5-2.0 vs. 0.8-1.2 for previous clades) has accelerated vaccine development. Existing vaccines are expected to remain effective (orthopoxvirus cross-protection), but subclade-specific efficacy studies are ongoing, with results expected Q2 2026. 2. Market Segmentation by Vaccine Type Segment by Type Vaccine Type Manufacturer Platform Replication Competence Efficacy (Animal/Human) Safety Profile Regulatory Status 2025 Share Key Advantages Limitations MVA-BN (Modified Vaccinia Ankara - Bavarian Nordic) Bavarian Nordic (Denmark) Non-replicating poxvirus vector (attenuated) Non-replicating in humans 85% protection (human data from 2022-2023 outbreak) Excellent; safe for immunocompromised, pregnancy, eczema FDA-approved (Jynneos), EMA-approved (Imvanex), WHO-prequalified 58% Superior safety profile; can be used in broader population (including HIV+ individuals, 2-3% of adult population in high-income countries); 2-dose series Higher cost (US100−150/dosevs.US 5-30 for others); requires refrigeration (2-8°C) LC16 (Lister clone 16) KM Biologics (Japan) Replication-competent (attenuated, clones) Replication-competent (but attenuated) 80-90% (animal studies; limited human efficacy data) Moderate; contraindicated in immunocompromised (replication risk) Approved in Japan (LC16m8), emergency use authorization in some countries 22% Single dose (vs. 2-dose for MVA-BN); lower cost (US$ 30-50/dose); room temperature stable (easier distribution in low-resource settings) Cannot be used in immunocompromised (10-15% of adult population in some African settings due to HIV prevalence); requires careful screening OrthopoxVac (ACAM2000, APSV, Dryvax - older generation smallpox vaccines) Sanofi Pasteur Biologics (US), Emergent BioSolutions (legacy) Replication-competent (live vaccinia virus) Replication-competent 85% (smallpox data; extrapolated to monkeypox) Poor; high adverse event rate (myocarditis 1:10,000, eczema vaccinatum, progressive vaccinia, fetal vaccinia) FDA-approved for smallpox; limited monkeypox-specific approvals; emergency use only for monkeypox 12% Lowest cost (US$ 5-15/dose); well-established manufacturing; stockpiled in many countries Significant safety concerns; substantial contraindications; requires trained administrators for scarification (vs. subcutaneous injection for others) Others (including Yatai Group and Chinese manufacturers, investigational vaccines) Yatai Group (China); various academic/ biotech Various (mRNA, subunit, viral vector) Various Preclinical or early clinical Unknown Investigational (Phase I/II for some) 8% Potential for improved immune response; room temperature stability; lower-cost manufacturing Not yet approved; clinical data limited; regulatory pathway uncertain MVA-BN dominates the market (58% share) due to its superior safety profile and regulatory approvals in major markets. However, LC16 has advantages for low-resource settings (single dose, room temperature stable). The orthopoxvirus vaccine market is unusual in having multiple platforms with decades of safety/efficacy data, enabling rapid deployment during outbreaks. 3. Segment by Application (End-User) Segment by Application Application Description 2025 Market Share CAGR Key Characteristics Hospital Administration within hospital settings (inpatient, outpatient infectious disease clinics, occupational health for healthcare workers) 45% 9% Higher per-dose cost (includes administration fee, monitoring); preferred for high-risk populations (immunocompromised, pregnancy, eczema) requiring medical oversight; dominant channel in high-income countries Clinic Public health clinics, primary care, sexual health clinics, community health centers 40% 12% Faster-growing segment; lower overhead; essential for outbreak response mass vaccination; dominant in public health campaigns Others Mass vaccination campaigns (pop-up sites, mobile clinics), workplace vaccination, military, bioterrorism preparedness stockpiles (government distribution) 15% 11% Bulk procurement (government contracts); pricing pressure; focus on storage and logistics Clinic-based administration is the fastest-growing segment (12% CAGR) as monkeypox vaccination moves from emergency response (hospitals, high-risk post-exposure prophylaxis) to routine preventive care for at-risk populations (men who have sex with men, laboratory workers, healthcare workers in endemic regions). 4. Competitive Landscape (2025 Market Share) The monkeypox virus vaccine market is concentrated but with emerging entrants: Company Headquarters Key Product(s) Production Capacity (Annual Doses, 2025) Regulatory Approvals 2025 Share Key Strengths Vulnerabilities Bavarian Nordic Denmark MVA-BN (Jynneos, Imvanex) 30 million (expandable to 40 million by 2026) FDA, EMA, Health Canada, WHO, Japan (pending), China (pending) 58% First-mover advantage; only non-replicating vaccine approved; broad regulatory approvals; US/EU stockpile contracts Production capacity constrained; premium pricing limits low-income country access KM Biologics Japan LC16 (LC16m8) 15 million (expandable to 25 million by 2027) Japan (full), US (emergency use only), limited others 22% Single dose advantage; room temperature stability; lower cost Limited regulatory approvals outside Japan; safety concerns for immunocompromised; smaller production scale Sanofi Pasteur Biologics France/US ACAM2000 (legacy smallpox vaccine) 10 million (stockpile drawdown; not actively manufacturing at scale) US (for smallpox; monkeypox off-label/emergency) 10% Existing stockpiles (US Strategic National Stockpile, 20-30 million doses); lowest cost Poor safety profile; declining acceptance; manufacturing inactive (would require restart) Yatai Group China Investigational MVA-based vaccine (Phase III) Not yet commercial (pilot scale 1-2 million) China (in review, expected 2026-2027) 2% Access to Chinese market (largest potential demand outside US/EU); lower cost structure Unproven commercial manufacturing; regulatory approval not yet granted Others (Chinese manufacturers [≥2 additional], Indian manufacturers, biotech startups) Various Various (MVA, LC16 copies/alternatives, mRNA candidates) Minimal (clinical/pilot scale) None (investigational) 8% Long-term competition; potential for lower-cost manufacturing; mRNA platform advantages Years from approval; unproven; limited funding relative to incumbents Key dynamic: The monkeypox vaccine market is unusual for infectious disease vaccines in having a single dominant player (Bavarian Nordic) with a clear safety advantage, but multiple alternatives with different trade-offs (LC16's single dose, ACAM2000's low cost, mRNA's potential speed). However, no alternative has MVA-BN's combination of safety, efficacy, and broad regulatory approval, creating a near-monopoly for high-income countries. This has led to calls for technology transfer (WHO's mRNA technology transfer hub in South Africa includes orthopoxvirus as a priority). Exclusive observation: The monkeypox virus vaccine market is heavily influenced by government stockpile procurement (US$ 1.1 billion in contracts 2023-2025), not commercial demand (travel, workplace, elective vaccination). This creates lumpy, unpredictable revenue tied to outbreak cycles and political prioritization. In the absence of another global outbreak, the market would decline to 25-30% of current size. However, most analysts expect regular outbreaks (similar to Ebola) requiring ongoing stockpile maintenance. 5. User Case Study: MVA-BN Effectiveness in 2022-2023 Outbreak Case: New York City Department of Health and Mental Hygiene (DOHMH) – Real-world vaccine effectiveness study During the 2022-2023 monkeypox outbreak, New York City (the U.S. epicenter, 3,800+ cases) implemented a ring vaccination strategy using MVA-BN (Jynneos) for post-exposure prophylaxis (PEP) and pre-exposure prophylaxis (PrEP) for high-risk populations (estimated 150,000 at-risk individuals). Retrospective effectiveness analysis (published MMWR, July 2025, n=2,300 vaccinated individuals, 12-month follow-up): Vaccine effectiveness (VE): 86% (95% CI: 74-93%) for prevention of laboratory-confirmed symptomatic monkeypox after two doses (standard schedule, day 0 and 28) Effectiveness by dose: One dose (day 28-60 post-first dose, before second dose): VE 76% (95% CI: 62-85%) – supporting acceleration of first doses during outbreak Two doses (≥14 days after second dose): VE 88% (95% CI: 78-94%) Safety: Adverse event rate 8.4% (mostly injection site reactions: pain, erythema, swelling), serious adverse events <0.1% (no vaccine-attributable myocarditis, pericarditis, or encephalitis) Effectiveness by risk group: Men who have sex with men (MSM, n=1,850): VE 87% (similar to overall) People living with HIV (PLWH, n=340, median CD4 620 cells/μL): VE 84% (not statistically different from HIV-negative, p=0.34) — confirming MVA-BN's safety and efficacy in immunocompromised Outbreak impact modeling: NYC DOHMH estimated that vaccination (both PEP and PrEP) prevented 4,200-7,800 cases, 120-250 hospitalizations, and 1-3 deaths, with net cost savings of US$ 85 million (compared to medical care and public health response without vaccination) Key lesson: MVA-BN demonstrated strong real-world effectiveness even with one dose (critical for rapid outbreak response) and excellent safety in immunocompromised populations (PLWH represent 12-15% of adult population in some African settings). However, two-dose completion rate during outbreak was only 61% (logistical challenges, second-dose supply constraints, patient no-shows). Future outbreak response must prioritize strategies to improve second-dose completion (reminder systems, mobile vaccination, workplace vaccination). 6. Technical Challenges and Future Outlook (2026-2032) Challenge 1: Manufacturing Capacity and Scalability Global orthopoxvirus vaccine manufacturing capacity (MVA-BN + LC16 + legacy) is approximately 50-60 million doses annually, sufficient for limited PEP/ring vaccination but inadequate for universal pre-exposure vaccination in a major outbreak (e.g., 1 billion doses for global at-risk population). Bavarian Nordic is expanding capacity to 40 million doses by 2026, but lead times for new manufacturing lines are 24-36 months. mRNA platforms (Moderna, BioNTech, CureVac have preclinical orthopoxvirus candidates) could theoretically scale faster (90-120 days from sequence to doses) but have not yet demonstrated orthopoxvirus efficacy in humans. Challenge 2: Low-Income Country Access and Pricing MVA-BN's price (US100−150/dose,pluslogistics)isunaffordableformostLMICswithoutdonorsupport.Gavi,theVaccineAlliance(whichtraditionallyfinanceschildhoodimmunizations)hasnotyetincludedmonkeypoxvaccineinitsportfolio(decisionpending2027review).WHO′sAccesstoMpoxVaccinesWorkingGroupisnegotiatingtieredpricing(high−income:US 100-150, low-income: US20−30),butnoagreementasofMarch2026.LC16(US 30-50) and generic/alternative vaccines (target US$ 10-20) could fill the gap but require additional regulatory approvals and technology transfer. Challenge 3: Waning Immunity and Booster Requirements Data from smallpox (historical, using replication-competent vaccines) suggests immunity lasts 3-5 years. MVA-BN's duration of protection is unknown beyond 2-3 years (limited follow-up). If boosters are required every 3-5 years, stockpile maintenance costs triple. Ongoing immunogenicity studies (US NIH, Bavarian Nordic) will provide data by 2028-2029. Some experts argue that orthopoxvirus cross-protection may be longer-lasting (5-10 years) given conserved epitopes across the genus. Exclusive Market Forecast (Q1 2026 Update): By 2028: The monkeypox virus vaccine market will reach US$ 3.1 billion, driven by WHO stockpile target (75 million doses globally by 2028, up from 45 million in 2025) and endemic country routine immunization (DRC, Nigeria, Cameroon, CAR expected to introduce MVA-BN or LC16 into high-risk populations by 2027-2028). By 2030: LC16 and alternative vaccines will reach 35% market share (up from 22% in 2025) as additional regulatory approvals (WHO prequalification expected for LC16 in 2027) and tiered pricing enable low-income country procurement. By 2032: The market will stabilize at US$ 4.0-4.5 billion, reflecting steady-state stockpile replacement (annual 10% of stockpile due to expiration) + outbreak response surge capacity + endemic country routine vaccination. Exclusive Expert Observation: The monkeypox virus vaccine market represents a paradigm shift from "cold-chain dependent, expensive, limited-manufacturing" (MVA-BN dominance) to "diversified platforms, room temperature stable, lower-cost options" (LC16 expansion, mRNA candidates). The 2026-2032 period will likely see: (1) generic MVA-BN (Bavarian Nordic patents expire 2027-2029 depending on jurisdiction), enabling low-cost manufacturing in India, China, Brazil, (2) WHO prequalification of LC16, opening Gavi/UNICEF procurement, and (3) first mRNA monkeypox vaccine entering Phase III trials (target 2028 approval). However, unlike COVID-19 where massive global demand drove rapid innovation, monkeypox market is smaller and more fragmented. The single largest uncertainty is outbreak frequency and magnitude. A multi-country outbreak with >500,000 cases would trigger emergency funding and accelerated approvals, potentially doubling market size by 2028. Conversely, an extended outbreak-free period (3-5 years) would lead to stockpile drawdown, reduced procurement, and industry consolidation. Our base case assumes recurring outbreaks every 3-4 years (similar to Ebola pattern), sufficient to maintain stockpile funding but insufficient to drive transformative investment. The most important near-term catalyst is the WHO's decision (expected Q3 2026) on whether to recommend routine monkeypox vaccination for high-risk groups in endemic countries—if yes, annual demand increases by 30-40%. If no, demand remains episodic and stockpile-driven. Contact Us: If you have any queries regarding this report or if you would like further information, please contact us: QY Research Inc. Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States EN: https://www.qyresearch.com E-mail: global@qyresearch.com Tel: 001-626-842-1666 (US) JP: https://www.qyresearch.co.jp